Sigrid Jusélius Foundation has announced the outcome of the application of Senior Researcher grants in 2021. Dr. Jianwei Li, a group leader at the MediCity Research Laboratory, is one of the five awardees, and will receive 700 000 € to develop nanomaterials for cancer therapy from a systems chemistry perspective.
The Cancer Biology laboratories of Klaus Elenius and Kari Kurppa are looking for a doctoral candidate to join a collaborative project of the two laboratories in the University of Turku, Turku, Finland.
InFLAMES (Innovation Ecosystem based on the Immune System) is a Finnish research flagship that aims at identifying novel drug targets using the most modern technological platforms and finding novel diagnostic tools to identify the patients benefitting from personalised therapies.
A research group at the University of Turku, Finland, has discovered a completely new mechanism that cells use to circulate integrins on the cell surface. Aggressive breast cancer cells exploit this mechanism to spread and metastasise to other parts of the body.
Researchers at the University of Turku, Finland, showed that the antibody treatment reactivates the immune defense in patients with advanced-stage cancer. The treatment alters the function of the body’s phagocytes and facilitates extensive activation of the immune system.
Notch proteins are key regulators of growth and differentiation of both normal and cancer cells. Researchers in Turku, Finland, have now demonstrated that the activities of distinct Notch family members are modified differently by phosphorylation. These results can be used in the development of new cancer treatments, especially for hormone-dependent breast cancer.
The Cancer Biology laboratories of Klaus Elenius and Kari Kurppa are looking for a doctoral candidate to join a collaborative project.
Melanoma Immune Oncology Research Group (MIORG) is looking for two doctoral candidates to join the group on a fixed-term grant-based position, supervised by the group leader Dr Rogerio de Figueiredo.
SORLA is a protein trafficking receptor that has been mainly studied in neurons, but it also plays a role in cancer cells. Professor Johanna Ivaska’s research group at Turku Bioscience observed that SORLA functionally contributes to the most reported therapy-resistant mechanism by which the cell-surface receptor HER3 counteracts HER2 targeting therapy in HER2-positive cancers. Removing SORLA from cancer cells sensitised anti-HER2 resistant breast cancer brain metastasis to targeted therapy.
A rapid test for ovarian cancer detection developed at the University of Turku has received the international Rapid Testing Innovation Award. The awarded article is part of the dissertation of Doctoral Candidate Sherif Bayoumy. Next, the cancer diagnostics team of the Biotechnology unit at the Department of Biochemistry aims to expand the research to other cancer types.